Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
US Department of Justice
Farmers Insurance
Johnson and Johnson
QuintilesIMS
Covington
Queensland Health
McKesson

Generated: November 12, 2018

DrugPatentWatch Database Preview

Allergan Sales Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN SALES LLC, and what generic alternatives to ALLERGAN SALES LLC drugs are available?

ALLERGAN SALES LLC has fifty-two approved drugs.

There are seventy-three US patents protecting ALLERGAN SALES LLC drugs.

Summary for Allergan Sales Llc
US Patents:73
Tradenames:52
Ingredients:38
NDAs:52
Patent Litigation for Allergan Sales Llc: See patent lawsuits for Allergan Sales Llc

Drugs and US Patents for Allergan Sales Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc FETZIMA levomilnacipran hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 204168-002 Jul 25, 2013 RX Yes No 8,481,598 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc NAMZARIC donepezil hydrochloride; memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 206439-001 Dec 23, 2014 AB RX Yes No 8,058,291 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-004 Jan 14, 2009 AB RX Yes No 6,992,110 ➤ Sign Up ➤ Sign Up
Allergan Sales Llc ACTIGALL ursodiol CAPSULE;ORAL 019594-002 Dec 31, 1987 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Allergan Sales Llc VRAYLAR cariprazine hydrochloride CAPSULE;ORAL 204370-002 Sep 17, 2015 RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Allergan Sales Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc KADIAN morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 020616-008 Apr 20, 2007 5,202,128 ➤ Sign Up
Allergan Sales Llc LEXAPRO escitalopram oxalate TABLET;ORAL 021323-002 Aug 14, 2002 RE34712*PED ➤ Sign Up
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 5,164,190 ➤ Sign Up
Allergan Sales Llc RAPAFLO silodosin CAPSULE;ORAL 022206-002 Oct 8, 2008 5,760,485 ➤ Sign Up
Allergan Sales Llc BYSTOLIC nebivolol hydrochloride TABLET;ORAL 021742-005 Oct 8, 2008 5,759,580 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN SALES LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Suppository 1000 mg ➤ Subscribe 2013-05-24
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 2017-06-09
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 2017-07-25
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 2015-01-21
➤ Subscribe Capsules 21 mg/10 mg ➤ Subscribe 2016-09-23
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 2016-08-30
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 2012-10-09
➤ Subscribe Gel 10% ➤ Subscribe 2014-06-19
➤ Subscribe Capsules 5 mg ➤ Subscribe 2005-08-17
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 2007-10-16
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 2011-12-19
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 2013-01-14
➤ Subscribe Capsules 14 mg/10 mg and 28 mg/10 mg ➤ Subscribe 2015-05-18
➤ Subscribe Capsules 7 mg/10 mg ➤ Subscribe 2016-09-26
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 2014-08-12
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 2008-08-19
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 2014-10-29
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 2005-03-30

Supplementary Protection Certificates for Allergan Sales Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0443983/03 Switzerland ➤ Sign Up PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
2013 00027 Denmark ➤ Sign Up
6 Finland ➤ Sign Up
C0022 France ➤ Sign Up PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
156 Luxembourg ➤ Sign Up PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
McKesson
Baxter
AstraZeneca
UBS
Chinese Patent Office
Cerilliant
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.